Related Experiment Video
Updated: Sep 25, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Comparison of Cell Line-Derived and Patient-Derived Xenograft Technologies in Oncology (Review)
E A Gantsova1,2, I V Arutyunyan3,4, G D Perevyazkina3
1Research Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow, Russia. gantsova@mail.ru.
Abstract:
The review evaluates the potential of preclinical in vivo modeling of human tumors. Two fundamental xenograft technologies, cell line-derived xenograft (CDX) and patient-derived xenograft (PDX), are described and their roles within the established methodological framework of translational biomedicine are characterized. The discussion covers practical aspects of model creation and the role of immunodeficient animals in the evolution of cancer modeling. Original data and the results of other research groups obtained in the study of tumor xenografts are analyzed. A comprehensive assessment of the advantages and limitations of CDX and PDX tumor models suggests that they play complementary, rather than competing, roles in modern preclinical oncology.
